文献速递神经肿瘤

三程术前立体定向放疗治疗可切除脑转移瘤:2期STEP试验

Three-fraction preoperative stereotactic radiotherapy for resectable brain metastases: the phase 2 STEP trial.
PubMed 文献 · Neuro Oncol · 2026-10-30

这项开放标签、单臂、多中心2期试验评估了三程术前立体定向放疗后3天内手术切除可切除脑转移瘤的疗效。63例患者接受治疗,6个月局部控制率达100%(95%CI 95%-100%),1年累积放射性坏死发生率为7%(95%CI 2%-16%),无软脑膜病变发生。结论认为术前SRT局部控制率高、放射性坏死低且无软脑膜病变,支持开展随机试验验证。

要点

  • 三程术前SRT后3天内手术,6个月局部控制率100%,12个月96.4%。
  • 1年累积指标病灶放射性坏死发生率7%,无软脑膜病变发生。
  • 远处颅内失败22例(35%),12个月总生存率81.2%,术后并发症4例(6.3%)。

核心结论

  • 三程术前SRT后手术切除可切除脑转移瘤与高局部控制率、低放射性坏死及无软脑膜病变相关,支持在正在进行的随机试验中进一步评估。

研究设计与样本

  • 开放标签、单臂、多中心2期试验,纳入Karnofsky体能状态≥70、最多4个脑转移灶(含1个≤5cm可切除病灶)的成人患者,来源于乳腺癌、非小细胞肺癌、肾癌、消化道癌或黑色素瘤。
  • 患者接受术前SRT(3程7.7Gy,处方至70%等剂量线,相当于等中心每程11Gy),末程后3天内行手术切除。
  • 主要终点为中心reviewed MRI评估的6个月局部控制率;次要终点包括指标病灶放射性坏死、软脑膜病变、远处颅内控制、总生存、毒性、认知和生活质量。
  • 73例评估患者中67例符合条件,63例同时接受SRT和手术;中位年龄62岁,中位随访12.7个月。

主要发现

  • 6个月局部控制率为100%(95%CI 95%-100%),达到主要终点;12个月局部控制率为96.4%(95%CI 87%-99%)。
  • 无软脑膜病变发生。
  • 指标病灶1年累积放射性坏死发生率为7%(95%CI 2%-16%),达到关键次要终点。
  • 远处颅内失败22例(35%);12个月总生存率为81.2%(95%CI 70%-89%)。
  • 术后并发症4例(6.3%);认知和生活质量在12个月方案随访期间保持稳定。

临床怎么用

  • 对于符合条件的可切除脑转移瘤患者,三程术前SRT后3天内手术可作为术后SRT的一种替代策略,具有高局部控制率和低放射性坏死风险。
  • 术前SRT可避免术后腔隙动态勾画、缩短局部治疗延迟并可能降低软脑膜病变风险,但需在随机试验证据成熟前谨慎选择患者。

局限性

  • 单臂设计,无同期对照组,结论需随机试验验证。
  • 样本量有限(63例接受治疗),随访时间较短(中位12.7个月)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Postoperative stereotactic radiotherapy (SRT) is the standard adjuvant treatment after resection of brain metastases. It nevertheless requires delineation of a dynamic postsurgical cavity, delays local treatment by 3 to 6 weeks (and thus resumption of systemic therapy) and carries substantial risks of radiation necrosis and leptomeningeal disease. Preoperative SRT targets an intact lesion and may address some of these limitations. METHODS: In this open-label, single-arm, multicenter phase 2 trial, eligible adults had a Karnofsky performance status ≥70 and up to four brain metastases, including one resectable lesion ≤5 cm, from breast, non-small cell lung, kidney, or digestive cancer or melanoma. Patients received preoperative SRT (three fractions of 7.7 Gy prescribed to the encompassing 70% isodose line, equivalent to 11Gy per fraction at the isocenter) followed by surgical resection within 3 days of the last fraction. The primary outcome was 6-month local control on centrally reviewed MRI. Secondary outcomes included index-lesion radiation necrosis, leptomeningeal disease, distant intracranial control, overall survival, toxicity, cognition, and quality of life. RESULTS: Of 73 patients assessed, 67 were eligible and 63 received both SRT and surgery. Median age was 62 years. At a median follow-up of 12.7 months, the 6-month local control rate was 100% (95% CI, 95%-100%), meeting the primary endpoint; the 12-month rate was 96.4% (95% CI, 87%-99%). No leptomeningeal disease occurred. The 1-year cumulative incidence of index-lesion radiation necrosis was 7% (95% CI, 2%-16%), meeting the key secondary endpoint. Distant intracranial failure occurred in 22 patients (35%); 12-month overall survival was 81.2% (95% CI, 70%-89%). Postoperative complications occurred in 4 patients (6.3%); cognition and quality of life remained stable over the 12 months of protocol follow-up. CONCLUSIONS: Three-fraction preoperative SRT followed by resection was associated with high local control, low radiation necrosis, and no leptomeningeal disease, supporting evaluation in ongoing randomized trials. Brain metastases are cancers that have spread to the brain. When a tumor is removed by surgery, radiation is usually given afterward to lower the chance it comes back, but this can cause side effects and the cancer can still return or spread across the lining of the brain. This study tested giving radiation before surgery instead, in three sessions. Among 63 patients, none had the treated tumor regrow within six months, serious radiation-related damage was rare, and the dangerous spread across the brain lining did not occur. Giving radiation before surgery appears safe and effective and deserves further study.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Biau, Thillays, Le Fèvre, et al. Three-fraction preoperative stereotactic radiotherapy for resectable brain metastases: the phase 2 STEP trial. Neuro Oncol. 2026. PMID: 42960872. doi:10.1093/neuonc/noag267

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。